Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in District of Columbia: - Georgetown University Lombardi Cancer Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
Sponsor: SignPath Pharma, Inc.
NCT ID: NCT05768919
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Network
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…
Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherap…
Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04323046
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
EARLY Phase 1 Recruiting Academic/Other
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with che…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06333899
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
EARLY Phase 1 Recruiting Academic/Other
This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come back, gotten worse, or didn't get better with earlier treatments. The main ques…
Sponsor: Children's National Research Institute
NCT ID: NCT07017816
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from …
Sponsor: Children's National Research Institute
NCT ID: NCT06193759
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 4 Recruiting Industry
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT03975829
Sites in District of Columbia: - Childrens National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05839379
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during su…
Sponsor: University of California, San Francisco
NCT ID: NCT05057702
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed wi…
Sponsor: Children's National Research Institute
NCT ID: NCT05697874
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduc…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05658731
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT03223922
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the long-term…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07129317
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia